614PCANYON trial results: sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMDC. McDonald, J. Donovan, D. Castro et al.|Neuromuscular Disorders|2025Cited by 0